Study to Assess Monoclonal B-Cell Lymphocytosis in Individuals With Chronic Hepatitis C
Reason given: slow accrual
Key facts
- Where
- Rochester, United StatesSee the site
Where in United States
- Mayo Clinic in RochesterRochester, United StatesNo longer taking part
Trial details
- Who runs it
- Mayo Clinic
- Trial code
- NCT06564051
- Record updated
- 6 January 2026
- Original description
This study evaluates the incidence of monoclonal B-cell lymphocytosis MBL) in patients with chronic hepatitis C and to determine if monoclonal b-cell lymphocytosis is affected by treatment for hepatitis C.Read full original descriptionShow less
A Prospective Observational Study to Assess Monoclonal B-Cell Lymphocytosis in Individuals With Chronic Hepatitis C
This study evaluates the incidence of monoclonal B-cell lymphocytosis MBL) in patients with chronic hepatitis C and to determine if monoclonal b-cell lymphocytosis is affected by treatment for hepatitis C.
Inclusion: Individuals with chronic hepatitis C who are to begin therapy with DAA; Willing to submit a peripheral blood sample at baseline, end of therapy, 12 weeks after the end of therapy, and 52 weeks from baseline.
Exclusion: Individuals with chronic hepatitis C who have cirrhosis; Individuals with chronic hepatitis C who have a past history of a lymphoproliferative disorder AND for which they received chemotherapy.